000208154 001__ 208154
000208154 005__ 20180913063122.0
000208154 0247_ $$2doi$$a10.1097/Fpc.0000000000000131
000208154 022__ $$a1744-6872
000208154 02470 $$2ISI$$a000352267600004
000208154 037__ $$aARTICLE
000208154 245__ $$aImpact of HSD11B1 polymorphisms on BMI and components of the metabolic syndrome in patients receiving psychotropic treatments
000208154 260__ $$aPhiladelphia$$bLippincott Williams & Wilkins$$c2015
000208154 269__ $$a2015
000208154 300__ $$a13
000208154 336__ $$aJournal Articles
000208154 520__ $$aBackground Metabolic syndrome (MetS) associated with psychiatric disorders and psychotropic treatments represents a major health issue. 11 beta-Hydroxysteroid dehydrogenase type 1 (11 beta-HSD1) is an enzyme that catalyzes tissue regeneration of active cortisol from cortisone. Elevated enzymatic activity of 11 beta-HSD1 may lead to the development of MetS. Methods We investigated the association between seven HSD11B1 gene (encoding 11 beta-HSD1) polymorphisms and BMI and MetS components in a psychiatric sample treated with potential weight gain-inducing psychotropic drugs (n = 478). The polymorphisms that survived Bonferroni correction were analyzed in two independent psychiatric samples (n(R1) = 168, n(R2) = 188) and in several large population-based samples (n(1) = 5338; n(2) = 123 865; n(3) > 100 000). Results HSD11B1 rs846910-A, rs375319-A, and rs4844488-G allele carriers were found to be associated with lower BMI, waist circumference, and diastolic blood pressure compared with the reference genotype (P-corrected < 0.05). These associations were exclusively detected in women (n = 257) with more than 3.1 kg/m(2), 7.5 cm, and 4.2 mmHg lower BMI, waist circumference, and diastolic blood pressure, respectively, in rs846910-A, rs375319-A, and rs4844488-G allele carriers compared with noncarriers (P-corrected < 0.05). Conversely, carriers of the rs846906-T allele had significantly higher waist circumference and triglycerides and lower high-density lipoprotein-cholesterol exclusively in men (P-corrected = 0.028). The rs846906-T allele was also associated with a higher risk of MetS at 3 months of follow-up (odds ratio: 3.31, 95% confidence interval: 1.53-7.17, P-corrected = 0.014). No association was observed between HSD11B1 polymorphisms and BMI and MetS components in the population-based samples. Conclusions Our results indicate that HSD11B1 polymorphisms may contribute toward the development of MetS in psychiatric patients treated with potential weight gain-inducing psychotropic drugs, but do not play a significant role in the general population. Copyright (C) 2015 Wolters Kluwer Health, Inc. All rights reserved.
000208154 6531_ $$abody mass index
000208154 6531_ $$ametabolic syndrome
000208154 6531_ $$apharmacogenetics
000208154 6531_ $$apsychotropic drugs
000208154 700__ $$aQuteineh, Lina$$uUniv Lausanne Hosp, Ctr Psychiat Neurosci, Unit Pharmacogenet & Clin Psychopharmacol, Dept Psychiat, Prilly, Switzerland
000208154 700__ $$aVandenberghe, Frederik$$uUniv Lausanne Hosp, Inst Social & Prevent Med IUMSP, Lausanne, Switzerland
000208154 700__ $$aMorgui, Nuria Saigi$$uUniv Lausanne Hosp, Ctr Psychiat Neurosci, Unit Pharmacogenet & Clin Psychopharmacol, Dept Psychiat, Prilly, Switzerland
000208154 700__ $$aDelacretaz, Aurelie$$uUniv Lausanne Hosp, Ctr Psychiat Neurosci, Unit Pharmacogenet & Clin Psychopharmacol, Dept Psychiat, Prilly, Switzerland
000208154 700__ $$aChoong, Eva$$uUniv Lausanne Hosp, Ctr Psychiat Neurosci, Unit Pharmacogenet & Clin Psychopharmacol, Dept Psychiat, Prilly, Switzerland
000208154 700__ $$aGholam-Rezaee, Mehdi$$uUniv Lausanne Hosp, Ctr Psychiat Epidemiol & Psychopathol, Dept Psychiat, Prilly, Switzerland
000208154 700__ $$0243698$$aMagistretti, Pierre$$g134990$$uEcole Polytech Fed Lausanne, Brain Mind Inst, Lab Neuroenerget & Cellular Dynam, Lausanne, Switzerland
000208154 700__ $$aBondolfi, Guido$$uUniv Hosp Geneva, Dept Mental Hlth & Psychiat, Geneva, Switzerland
000208154 700__ $$aVon Gunten, Armin$$uUniv Lausanne Hosp, Serv Old Age Psychiat, Dept Psychiat, Prilly, Switzerland
000208154 700__ $$aPreisig, Martin$$uUniv Lausanne Hosp, Ctr Psychiat Epidemiol & Psychopathol, Dept Psychiat, Prilly, Switzerland
000208154 700__ $$aCastelao, Enrique$$uUniv Lausanne Hosp, Ctr Psychiat Epidemiol & Psychopathol, Dept Psychiat, Prilly, Switzerland
000208154 700__ $$aVollenweider, Peter$$uUniv Lausanne Hosp, Dept Med, Lausanne, Switzerland
000208154 700__ $$aWaeber, Gerard$$uUniv Lausanne Hosp, Dept Med, Lausanne, Switzerland
000208154 700__ $$aBochud, Murielle$$uUniv Lausanne Hosp, Inst Social & Prevent Med IUMSP, Lausanne, Switzerland
000208154 700__ $$aKutalik, Zoltan$$uUniv Lausanne Hosp, Inst Social & Prevent Med IUMSP, Lausanne, Switzerland
000208154 700__ $$aConus, Philippe$$uUniv Lausanne Hosp, Serv Gen Psychiat, Dept Psychiat, Prilly, Switzerland
000208154 700__ $$aEap, Chin B.$$uUniv Lausanne Hosp, Ctr Psychiat Neurosci, Unit Pharmacogenet & Clin Psychopharmacol, Dept Psychiat, Prilly, Switzerland
000208154 773__ $$j25$$k5$$q246-258$$tPharmacogenetics And Genomics
000208154 909C0 $$0252265$$pLNDC$$xU11150
000208154 909CO $$ooai:infoscience.tind.io:208154$$pSV$$particle
000208154 917Z8 $$x219572
000208154 937__ $$aEPFL-ARTICLE-208154
000208154 973__ $$aEPFL$$rREVIEWED$$sPUBLISHED
000208154 980__ $$aARTICLE